Polycystic ovary syndrome: Current scenario and future insights

Simple item page
dc.contributor.authorKulkarni, Swanand
dc.contributor.authorGupta, Khushi
dc.contributor.authorRatre, Pooja
dc.contributor.authorMishra, Pradyumna Kumar
dc.contributor.authorSingh, Yogesh
dc.contributor.authorBiharee, Avadh
dc.contributor.authorThareja, Suresh
dc.date.accessioned2024-01-21T10:38:39Z
dc.date.accessioned2024-08-13T12:05:36Z
dc.date.available2024-01-21T10:38:39Z
dc.date.available2024-08-13T12:05:36Z
dc.date.issued2023-11-05T00:00:00
dc.description.abstractPolycystic ovary syndrome (PCOS) prevails in approximately 33% of females of reproductive age globally. Although the root cause of the disease is unknown, attempts are made to clinically manage the disturbed hormone levels and symptoms arising due to hyperandrogenism, a hallmark of PCOS. This review presents detailed insights on the etiology, risk factors, current treatment strategies, and challenges therein. Medicinal agents currently in clinical trials and those in the development pipeline are emphasized. The significance of the inclusion of herbal supplements in PCOS and the benefits of improved lifestyle are also explained. Last, emerging therapeutic targets for treating PCOS are elaborated. The present review will assist the research fraternity working in the concerned domain to access significant knowledge associated with PCOS. � 2023 Elsevier Ltden_US
dc.identifier.doi10.1016/j.drudis.2023.103821
dc.identifier.issn13596446
dc.identifier.urihttp://10.2.3.109/handle/32116/3625
dc.identifier.urlhttps://linkinghub.elsevier.com/retrieve/pii/S1359644623003379
dc.language.isoen_USen_US
dc.publisherElsevier Ltden_US
dc.titlePolycystic ovary syndrome: Current scenario and future insightsen_US
dc.title.journalDrug Discovery Todayen_US
dc.typeReviewen_US
dc.type.accesstypeClosed Accessen_US

Files

Collections

Pharmaceutical Sciences and Natural Products - Research Publications